Cargando…
Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
PURPOSE: Cytomegalovirus (CMV) reactivation occurs frequently in patients with the acute respiratory distress syndrome (ARDS) and has been associated with increased mortality. However, it remains unknown whether this association represents an independent risk for poor outcome. We aimed to estimate t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747999/ https://www.ncbi.nlm.nih.gov/pubmed/26415682 http://dx.doi.org/10.1007/s00134-015-4071-z |
_version_ | 1782415045173444608 |
---|---|
author | Ong, David S. Y. Spitoni, Cristian Klein Klouwenberg, Peter M. C. Verduyn Lunel, Frans M. Frencken, Jos F. Schultz, Marcus J. van der Poll, Tom Kesecioglu, Jozef Bonten, Marc J. M. Cremer, Olaf L. |
author_facet | Ong, David S. Y. Spitoni, Cristian Klein Klouwenberg, Peter M. C. Verduyn Lunel, Frans M. Frencken, Jos F. Schultz, Marcus J. van der Poll, Tom Kesecioglu, Jozef Bonten, Marc J. M. Cremer, Olaf L. |
author_sort | Ong, David S. Y. |
collection | PubMed |
description | PURPOSE: Cytomegalovirus (CMV) reactivation occurs frequently in patients with the acute respiratory distress syndrome (ARDS) and has been associated with increased mortality. However, it remains unknown whether this association represents an independent risk for poor outcome. We aimed to estimate the attributable effect of CMV reactivation on mortality in immunocompetent ARDS patients. METHODS: We prospectively studied immunocompetent ARDS patients who tested seropositive for CMV and remained mechanically ventilated beyond day 4 in two tertiary intensive care units in the Netherlands from 2011 to 2013. CMV loads were determined in plasma weekly. Competing risks Cox regression was used with CMV reactivation status as a time-dependent exposure variable. Subsequently, in sensitivity analyses we adjusted for the evolution of disease severity until onset of reactivation using marginal structural modeling. RESULTS: Of 399 ARDS patients, 271 (68 %) were CMV seropositive and reactivation occurred in 74 (27 %) of them. After adjustment for confounding and competing risks, CMV reactivation was associated with overall increased ICU mortality (adjusted subdistribution hazard ratio (SHR) 2.74, 95 % CI 1.51–4.97), which resulted from the joint action of trends toward an increased mortality rate (direct effect; cause specific hazard ratio (HR) 1.58, 95 % CI 0.86–2.90) and a reduced successful weaning rate (indirect effect; cause specific HR 0.83, 95 % CI 0.58–1.18). These associations remained in sensitivity analyses. The population-attributable fraction of ICU mortality was 23 % (95 % CI 6–41) by day 30 (risk difference 4.4, 95 % CI 1.1–7.9). CONCLUSION: CMV reactivation is independently associated with increased case fatality in immunocompetent ARDS patients who are CMV seropositive. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00134-015-4071-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4747999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-47479992016-02-19 Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome Ong, David S. Y. Spitoni, Cristian Klein Klouwenberg, Peter M. C. Verduyn Lunel, Frans M. Frencken, Jos F. Schultz, Marcus J. van der Poll, Tom Kesecioglu, Jozef Bonten, Marc J. M. Cremer, Olaf L. Intensive Care Med Original PURPOSE: Cytomegalovirus (CMV) reactivation occurs frequently in patients with the acute respiratory distress syndrome (ARDS) and has been associated with increased mortality. However, it remains unknown whether this association represents an independent risk for poor outcome. We aimed to estimate the attributable effect of CMV reactivation on mortality in immunocompetent ARDS patients. METHODS: We prospectively studied immunocompetent ARDS patients who tested seropositive for CMV and remained mechanically ventilated beyond day 4 in two tertiary intensive care units in the Netherlands from 2011 to 2013. CMV loads were determined in plasma weekly. Competing risks Cox regression was used with CMV reactivation status as a time-dependent exposure variable. Subsequently, in sensitivity analyses we adjusted for the evolution of disease severity until onset of reactivation using marginal structural modeling. RESULTS: Of 399 ARDS patients, 271 (68 %) were CMV seropositive and reactivation occurred in 74 (27 %) of them. After adjustment for confounding and competing risks, CMV reactivation was associated with overall increased ICU mortality (adjusted subdistribution hazard ratio (SHR) 2.74, 95 % CI 1.51–4.97), which resulted from the joint action of trends toward an increased mortality rate (direct effect; cause specific hazard ratio (HR) 1.58, 95 % CI 0.86–2.90) and a reduced successful weaning rate (indirect effect; cause specific HR 0.83, 95 % CI 0.58–1.18). These associations remained in sensitivity analyses. The population-attributable fraction of ICU mortality was 23 % (95 % CI 6–41) by day 30 (risk difference 4.4, 95 % CI 1.1–7.9). CONCLUSION: CMV reactivation is independently associated with increased case fatality in immunocompetent ARDS patients who are CMV seropositive. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00134-015-4071-z) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-03-01 2016 /pmc/articles/PMC4747999/ /pubmed/26415682 http://dx.doi.org/10.1007/s00134-015-4071-z Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Ong, David S. Y. Spitoni, Cristian Klein Klouwenberg, Peter M. C. Verduyn Lunel, Frans M. Frencken, Jos F. Schultz, Marcus J. van der Poll, Tom Kesecioglu, Jozef Bonten, Marc J. M. Cremer, Olaf L. Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome |
title | Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome |
title_full | Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome |
title_fullStr | Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome |
title_full_unstemmed | Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome |
title_short | Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome |
title_sort | cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome |
topic | Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747999/ https://www.ncbi.nlm.nih.gov/pubmed/26415682 http://dx.doi.org/10.1007/s00134-015-4071-z |
work_keys_str_mv | AT ongdavidsy cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome AT spitonicristian cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome AT kleinklouwenbergpetermc cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome AT verduynlunelfransm cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome AT frenckenjosf cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome AT schultzmarcusj cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome AT vanderpolltom cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome AT kesecioglujozef cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome AT bontenmarcjm cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome AT cremerolafl cytomegalovirusreactivationandmortalityinpatientswithacuterespiratorydistresssyndrome |